Internal Medicine, Hematology & Oncology · Los Angeles, CA
NPI
1588735559
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
4733 W Sunset Blvd
Los Angeles, CA, 90027
Phone (323) 783-4011
Groups this clinician bills Medicare through
Medicare paid, 2022
$9,641
205 services
Medicare patients, 2022
14
Average age 66
Drug cost, 2024
$5.1M
1,911 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Michael B Glowalla prescribed most often to Medicare patients was Lenalidomide, with 90 prescriptions and refills. In total Michael B Glowalla wrote 1,911 Medicare prescriptions that cost $5.1M.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-12-01.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Lenalidomide Generic | 90 | 90 | 14 | $1.1M |
| Brukinsa Zanubrutinib | 83 | 83 | 11 | $1.0M |
| Acyclovir Generic | 78 | 207 | 32 | $2,031 |
| Hydroxyurea Generic | 71 | 217 | 27 | $3,786 |
| Xarelto Rivaroxaban | 68 | 119 | 15 | $54K |
| Anastrozole Generic | 64 | 192 | 30 | $1,819 |
| Prednisone Generic | 60 | 139 | 25 | $850 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 51 | 51 | 13 | $1,965 |
| Hydromorphone Hcl Generic | 50 | 50 | Under 11 | $3,442 |
| Omeprazole Generic | 48 | 141 | 24 | $648 |
| Pomalyst Pomalidomide | 45 | 45 | Under 11 | $948K |
| Procrit Epoetin Alfa | 45 | 45 | Under 11 | $133K |
| Pradaxa Dabigatran Etexilate Mesylate | 45 | 125 | 16 | $12K |
| Dexamethasone Generic | 39 | 70 | 19 | $808 |
| Gabapentin Generic | 39 | 105 | 11 | $794 |
Brand drugs: - claims; generic drugs: 1,379 claims; opioid claims: 159.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Michael B Glowalla were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.